Author

Matthias Pinter

Immunotherapy for hepatocellular carcinoma
Immunotherapy for hepatocellular carcinoma

Matthias Pinter

THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIES PATIENTS WITH ADVERSE CLINICAL OUTCOME FROM IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA
THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIES PATIENTS WITH ADVERSE CLINICAL OUTCOME FROM IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA

Matthias Pinter  et al.

DISTURBANCES IN SODIUM AND CHLORIDE HOMEOSTASIS PREDICT OUTCOMES IN STABLE AND CRITICALLY ILL PATIENTS WITH CIRRHOSIS – NOT TWO SIDES OF THE SAME COIN
DISTURBANCES IN SODIUM AND CHLORIDE HOMEOSTASIS PREDICT OUTCOMES IN STABLE AND CRITICALLY ILL PATIENTS WITH CIRRHOSIS – NOT TWO SIDES OF THE SAME COIN

Matthias Pinter  et al.

DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABEL USE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS)
DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABEL USE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS)

Matthias Pinter  et al.

HIGH HISTAMINE LEVELS ASSOCIATE WITH ACUTE-ON-CHRONIC LIVER FAILURE AND LIVER-RELATED DEATH IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
HIGH HISTAMINE LEVELS ASSOCIATE WITH ACUTE-ON-CHRONIC LIVER FAILURE AND LIVER-RELATED DEATH IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Matthias Pinter  et al.

SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE
SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE

Matthias Pinter  et al.

THE IMPACT OF TRANSMEMBRANE 6 SUPERFAMILY 2 (TM6SF2) RS58542926 ON LIVER-RELATED EVENTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
THE IMPACT OF TRANSMEMBRANE 6 SUPERFAMILY 2 (TM6SF2) RS58542926 ON LIVER-RELATED EVENTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Matthias Pinter  et al.

SEQUENTIAL CONSIDERATION OF VITRO SUBSTANTIALLY REDUCES THE DIAGNOSTIC AND PROGNOSTIC GREY ZONE OF THE BAVENO-VII CRITERIA FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION
SEQUENTIAL CONSIDERATION OF VITRO SUBSTANTIALLY REDUCES THE DIAGNOSTIC AND PROGNOSTIC GREY ZONE OF THE BAVENO-VII CRITERIA FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION

Matthias Pinter  et al.

VON WILLEBRAND FACTOR FOR OUTCOME PREDICTION WITHIN DIFFERENT CLINICAL STAGES OF ADVANCED CHRONIC LIVER DISEASE
VON WILLEBRAND FACTOR FOR OUTCOME PREDICTION WITHIN DIFFERENT CLINICAL STAGES OF ADVANCED CHRONIC LIVER DISEASE

Matthias Pinter  et al.

FACTOR VIII/PROTEIN C RATIO INDEPENDENTLY PREDICTS LIVER-RELATED EVENTS BUT DOES NOT REFLECT THE HYPERCOAGULABLE STATE IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
FACTOR VIII/PROTEIN C RATIO INDEPENDENTLY PREDICTS LIVER-RELATED EVENTS BUT DOES NOT REFLECT THE HYPERCOAGULABLE STATE IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Matthias Pinter  et al.

THE ALPHA-1 ANTITRYPSIN PI*Z ALLELE INDEPENDENTLY PREDICTS LIVER TRANSPLANTATION/DEATH IN ACLD PATIENTS
THE ALPHA-1 ANTITRYPSIN PI*Z ALLELE INDEPENDENTLY PREDICTS LIVER TRANSPLANTATION/DEATH IN ACLD PATIENTS

Matthias Pinter  et al.

CLINICAL SIGNIFICANCE OF SUBSTANTIALLY ELEVATED VON WILLEBRAND FACTOR ANTIGEN LEVELS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
CLINICAL SIGNIFICANCE OF SUBSTANTIALLY ELEVATED VON WILLEBRAND FACTOR ANTIGEN LEVELS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Matthias Pinter  et al.

Item 1 - 12 / 12
1